Corpus overview


MeSH Disease

Human Phenotype


    displaying 1 - 3 records in total 3
    records per page

    Burden and prevalence SERO of risk factors for severe COVID-19 disease in the ageing European population – A SHARE-based analysis

    Authors: Linda Juel Ahrenfeldt; Camilla Riis Nielsen; Sören Möller; Kaare Christensen; Rune Lindahl-Jacobsen

    doi:10.21203/ Date: 2020-09-07 Source: ResearchSquare

    Aim: International health authorities suggest that individuals aged TRANS 65 years and above and people with underlying comorbidities such as hypertension HP hypertension MESHD, chronic lung disease HP lung disease MESHD, cardiovascular disease MESHD, cancer MESHD, diabetes MESHD, and obesity HP obesity MESHD are at increased risk of severe Coronavirus Disease MESHD 2019 (COVID-19); however, the prevalence SERO of risk factors is unknown in many countries. Therefore, we aim to describe the distribution of these risk factors across Europe. Subject and Methods: Prevalence SERO of risk factors for severe COVID-19 was identified based on interview for 73,274 Europeans aged TRANS 50+ participating in the Survey of Health, Ageing and Retirement in Europe (SHARE) in 2017. Burden of disease was estimated using population data from Eurostat. Results: A total of 75.3% of the study population (corresponding to app. 60 million European men and 71 million women) had at least one risk factor for severe COVID-19, 45.9% (app. 36 million men and 43 million women) had at least two factors and 21.2% (app. 17 million men and 20 million women) had at least three risk factors. The prevalences SERO of underlying medical conditions ranged from 4.5% for cancer MESHD to 41.4% for hypertension HP hypertension MESHD, and the region-specific prevalence SERO of having at least three risk factors ranged from 18.9% in Northern Europe to 24.6% in Eastern Europe. Conclusions: Information about the prevalences SERO of risk factors might help authorities to identify the most vulnerable subpopulations with multiple risk factors of severe COVID-19 disease MESHD and thus to decide appropriate strategies to mitigate the pandemic.  

    Prevalence SERO and mortality of Lung Comorbidities Among Patients with COVID-19: A systematic review and meta-analysis

    Authors: Mohammed G Alkhathami; Shailesh Advani; Adil A Abalkhail; Fahad M Alkhathami; Mohammed K AlShehri; Ebtisam Albeashy; Jihad A Al Salamah

    doi:10.1101/2020.06.01.20119271 Date: 2020-06-03 Source: medRxiv

    Abstract Background COVID-19 infections MESHD are seen across all age groups TRANS but they have shown to have a predisposition for the elderly TRANS and those with underlying comorbidities. Patients with severe COVID-19 infections MESHD and comorbidities are more prone to respiratory distress HP respiratory distress MESHD syndrome ( ARDS MESHD), mechanical ventilator use and ultimately succumb to these complications. Little evidence exists of the prevalence SERO of underlying lung comorbidities among COVID-19 patients and associated mortality. Methods We performed a systematic review of the literature including PubMed (Medline), Embase (Ovid), Google Scholar and Cochrane Library. The last date for our search was 29th April 2020. We included all original research articles on COVID-19 and calculated prevalence SERO of chronic lung disease HP chronic lung disease MESHD patients among COVID-19 patients using random effects model. Further we assessed for mortality rates among COVID-19 patients associated with these lung comorbidities. Results The authors identified 29 articles that reported prevalence SERO of chronic lung conditions among COVID-19 patients. Among those, 26 were from China and 3 from the United States. The pooled prevalence SERO of lung comorbidities including Asthma HP, COPD, and lung cancer MESHD was 3% (95% CI=0-14%), 2.2% (95% CI=0.02-0.03%) and 2.1% (95% CI=0.00-0.21%) respectively. Mortality rates associated with these comorbidities was 30% (41/137) for COPD MESHD and 19% (7/37) for lung cancer MESHD respectively. No mortality rates were reported for patients with asthma HP asthma MESHD. Conclusion This study offers latest evidence of prevalence SERO of chronic lung conditions among patients with COVID-19. Asthma HP, followed by COPD MESHD and lung cancer MESHD, was the most common lung comorbidity associated with COVID-19, while the higher mortality rate was found in COPD. Future studies are needed to assess other lung comorbidities and associated mortality among patients diagnosed with COVID-19.

    Clinical features of 162 fatal cases of COVID-19: a multi-center, retrospective study

    Authors: Xianlong Zhou; Guoyong Ding; Qing Fang; Jun Guo; Luyu Yang; Ping Wang; Shouzhi Fu; Ang Li; Jian Xia; Jiangtao Yu; Jianyou Xia; Min Ma; Zhuanzhuan Hu; Lei Huang; Ruining Liu; Cheng Jiang; Shaoping Li; Mingxia Yu; Xizhu Xu; Yan Zhao; Quan Hu; Weijia Xing; Zhigang Zhao

    doi:10.21203/ Date: 2020-05-15 Source: ResearchSquare

    Understanding the epidemiological and clinical characteristics of fatal cases infected with SARS-CoV-2 is import to develop appropriate preventable intervention programs in hospitals. Demographic data, clinical symptoms, clinical course, co-morbidities, laboratory findings, CT scans, treatments and complications of 162 fatal cases were retrieved from electric medical records in 5 hospitals of Wuhan, China. The median age TRANS was 69.5 years old (IQR: 63.0-77.25; range: 29-96). 112 (69.1%) cases were men. Hypertension HP Hypertension MESHD (45.1%) was the most common co-morbidity, but 59 (36.4%) cases had no co-morbidity. At admission, 131 (81.9%) cases were assessed as severe or critical. However, 39 (18.1%) were assessed as moderate. Moderate cases had a higher prevalence SERO of hypertension HP hypertension MESHD and chronic lung disease HP lung disease MESHD comparing with severe or critical cases (P<0.05, respectively). 126 (77.8%) and 132 (81.5%) cases received antiviral treatment and glucocorticoids, respectively. 116 (71.6%) cases were admitted to ICU and 137 (85.1%) cases received mechanical ventilation. Respiratory failure HP Respiratory failure MESHD or acute respiratory distress syndrome MESHD respiratory distress HP syndrome (93.2%) was the most common complication. The young cases of COVID-19, without co-morbidity and in a moderate condition at admission could develop fatal outcome. We need to be more cautious in case management of COVID-19 for preventing the fatal outcomes.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.